Alger

Forte Biosciences is a biotechnology company specializing in dermatology and biopharmaceuticals. The company's lead product, FB-401, is a topically applied live biotherapeutic designed to treat inflammatory skin diseases, developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Additionally, Forte Biosciences is advancing another product candidate, FB-102, which is a proprietary therapeutic molecule aimed at addressing a range of autoimmune conditions, including graft-versus-host disease, vitiligo, and alopecia areata. The company is currently in the preclinical trial stage for FB-102, reflecting its commitment to developing innovative treatments for dermatological and autoimmune disorders.

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

Redwood Investments, LLC is an employee-owned investment manager based in Newton, Massachusetts, founded in 2004. The firm primarily serves high net worth individuals, as well as institutional clients, including investment companies, pension plans, charitable organizations, and corporations. Redwood specializes in managing client-focused equity portfolios across global public markets, investing in a diverse range of growth, blend, and value stocks from small-cap, mid-cap, and large-cap companies. Its investment strategy involves a combination of quantitative and fundamental analysis, employing a bottom-up stock picking approach. The firm also offers Sustainable Investing strategies that incorporate environmental, social, and corporate governance factors. Redwood's experienced portfolio management team is dedicated to delivering superior investment performance and attentive client service.

Forte Biosciences is a biotechnology company specializing in dermatology and biopharmaceuticals. The company's lead product, FB-401, is a topically applied live biotherapeutic designed to treat inflammatory skin diseases, developed in collaboration with the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Additionally, Forte Biosciences is advancing another product candidate, FB-102, which is a proprietary therapeutic molecule aimed at addressing a range of autoimmune conditions, including graft-versus-host disease, vitiligo, and alopecia areata. The company is currently in the preclinical trial stage for FB-102, reflecting its commitment to developing innovative treatments for dermatological and autoimmune disorders.

Impulse Dynamics N.V. is a medical device company focused on developing electrical therapies for chronic heart failure, operating primarily in the United States and Europe. The company's key innovation is its cardiac contractility modulation (CCM) therapy, which utilizes non-excitatory electrical impulses delivered to the heart muscles. This therapy aims to enhance cardiac strength and improve blood flow, offering a minimally invasive treatment option for patients with limited alternatives. Impulse Dynamics conducts clinical trials to assess the safety and efficacy of its therapies and collaborates with universities and hospitals for research initiatives. Founded in 1996 and headquartered in Willemstad, Curacao, the company also maintains offices in New York and Hong Kong, alongside product development centers in New Jersey and Israel.

Weatherbie Capital, LLC is an employee-owned investment management firm based in Boston, Massachusetts. Founded in December 1995 by Matthew Weatherbie, the firm specializes in managing growth equity portfolios, focusing primarily on small- and mid-cap companies in the United States. It provides investment services to a diverse clientele, including individuals, corporations, and various institutional entities such as pension plans and charitable organizations. Weatherbie Capital employs a fundamental, bottom-up research approach to identify and invest in attractive growth stocks, which has led to a strong record of performance over its two decades of operation. The firm also manages equity mutual funds and conducts in-house research to inform its investment decisions. In 2017, Weatherbie Capital became a subsidiary of Alger Associates Inc.

Prosetta Biosciences, Inc. is a biotechnology company based in San Francisco, California, founded in 2002. It specializes in developing novel small-molecule antiviral therapeutics using an innovative drug discovery platform that employs cell-free protein synthesizing systems. This approach allows for the identification of active compounds that may be overlooked by traditional pharmaceutical screening methods. Prosetta's research addresses a broad range of human diseases, including oncology, neurodegenerative disorders, and infectious diseases, and the company collaborates with both commercial partners and non-profit organizations to advance its compounds. Through its efforts, Prosetta Biosciences aims to enable healthcare professionals to discover and utilize small molecules that effectively modulate the assembly of multi-protein complexes within cells.

Tolero Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing innovative therapeutics for cancer and other serious diseases in the United States. Founded in 2011 and based in Salt Lake City, Utah, Tolero's product pipeline includes several promising candidates. TP-0413 targets a signaling pathway involved in serum iron regulation for patients with chronic inflammatory diseases, while TP-0903 is a dual-targeted agent that inhibits pathways critical for pancreatic cancer cell growth and tumor maintenance. Additional compounds under development include TP-0829, which addresses B-cell lymphomas and leukemia, and TP-0227, aimed at endometrial carcinomas. The company also explores TP-1149 to combat drug resistance in myeloma cells. Tolero Pharmaceuticals operates as a subsidiary of Dainippon Sumitomo Pharma America Holdings, Inc. and has established a partnership with MannKind Corporation to enhance its therapeutic development efforts.

Tolero Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering and developing innovative therapeutics for cancer and other serious diseases in the United States. Founded in 2011 and based in Salt Lake City, Utah, Tolero's product pipeline includes several promising candidates. TP-0413 targets a signaling pathway involved in serum iron regulation for patients with chronic inflammatory diseases, while TP-0903 is a dual-targeted agent that inhibits pathways critical for pancreatic cancer cell growth and tumor maintenance. Additional compounds under development include TP-0829, which addresses B-cell lymphomas and leukemia, and TP-0227, aimed at endometrial carcinomas. The company also explores TP-1149 to combat drug resistance in myeloma cells. Tolero Pharmaceuticals operates as a subsidiary of Dainippon Sumitomo Pharma America Holdings, Inc. and has established a partnership with MannKind Corporation to enhance its therapeutic development efforts.

ChoiceStream is a digital advertising service that specializes in programmatic advertising, focusing on cross-device branding and direct response campaigns for brand and agency clients. The company manages all phases of advertising campaigns, from pre-launch planning to completion, ensuring efficiency and effectiveness in reaching target audiences. By utilizing proprietary, poll-based data tailored to individual campaigns, ChoiceStream creates custom, targetable audiences and optimizes campaign results in real time. The company employs advanced machine-learning algorithms alongside a dedicated team of industry experts, which contributes to an impressive client retention rate of 83%, significantly higher than the industry average. This blend of innovative technology and personalized service enables clients to achieve their advertising goals effectively.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.